Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERELZI vs CYLTEZO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erelzi (etanercept-szzs) is a tumor necrosis factor (TNF) blocker. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) TNF receptor linked to the Fc portion of human Ig G1. Erelzi binds specifically to TNF-alpha and blocks its interaction with cell surface TNF receptors, thereby reducing TNF-mediated inflammatory responses.
Adalimumab is a recombinant human monoclonal antibody that binds to tumor necrosis factor-alpha (TNFα) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecules, chemotaxis, and matrix metalloproteinases.
Rheumatoid arthritis (moderately to severely active),Polyarticular juvenile idiopathic arthritis (moderate to severe),Psoriatic arthritis,Ankylosing spondylitis,Plaque psoriasis (chronic moderate to severe)
Rheumatoid arthritis (moderate to severe active disease),Juvenile idiopathic arthritis (polyarticular, 2 years and older),Psoriatic arthritis,Ankylosing spondylitis,Adult Crohn's disease (moderate to severe, anti-TNF naïve),Ulcerative colitis (moderate to severe in adults),Plaque psoriasis (moderate to severe chronic, adult),Hidradenitis suppurativa (moderate to severe, adult),Uveitis (non-infectious intermediate, posterior, and panuveitis in adults and pediatrics)
For plaque psoriasis: 100 mg subcutaneous injection once weekly, after initial loading dose of 200 mg at weeks 0, 1, 2, 3, and 4. For psoriatic arthritis: 100 mg subcutaneous injection once weekly.
Adalimumab 40 mg subcutaneously every other week, with or without methotrexate, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. For ulcerative colitis and hidradenitis suppurativa, day 1: 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two days), day 15: 80 mg, then 40 mg every other week starting day 29. For uveitis, 40 mg every other week.
Terminal elimination half-life: 13–16 days (mean 14.6 days) in adults with moderate-to-severe plaque psoriasis; clinical context: supports every-2-week subcutaneous dosing regimen.
Approximately 14 days (range 10–20 days) following subcutaneous administration; supports every-other-week dosing.
Erelzi is a monoclonal antibody-based fusion protein. It is expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes have been identified; it is not metabolized by cytochrome P450 enzymes.
Adalimumab is a monoclonal antibody; it is degraded by proteolytic enzymes into small peptides and amino acids. No specific metabolic pathways or CYP450 enzymes involved.
Renal: negligible (not significantly excreted unchanged); Biliary/Fecal: primary elimination pathway via proteolytic catabolism to amino acids; approximately 95% of dose recovered as small peptides/amino acids in feces.
Primarily eliminated via intracellular catabolism; no significant renal or biliary elimination of intact adalimumab.
Approximately 95–98% bound; primarily to endogenous immunoglobulins (Ig G) via Fc Rn binding; minimal binding to albumin or other plasma proteins.
Adalimumab binds specifically to soluble and membrane-bound TNF-alpha; does not bind to other serum proteins; binding to specific target is high affinity but no general protein binding data reported.
Volume of distribution: 3.5–4.0 L (approximately 0.05 L/kg for a 70 kg adult), indicating limited extravascular distribution, predominantly confined to vascular space and interstitial fluid.
Approximately 4.7–6.0 L (0.07–0.09 L/kg for a 70 kg adult); indicates distribution primarily within the vascular and interstitial spaces.
Subcutaneous: absolute bioavailability approximately 75–80% following injection into thigh, abdomen, or upper arm.
Subcutaneous: 64% (absolute bioavailability).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²); use with caution.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment.
No formal studies in hepatic impairment. Use with caution in Child-Pugh Class B or C due to potential altered clearance.
No dose adjustment recommended. Not studied in patients with hepatic impairment.
Safety and efficacy not established in pediatric patients <18 years old; no approved dosing.
For juvenile idiopathic arthritis (2 years and older): 10-30 mg subcutaneously every other week (10 mg if <15 kg, 20 mg if 15-30 kg, 40 mg if ≥30 kg). For pediatric plaque psoriasis (4 years and older): weight-based dosing with maximum 40 mg starting dose, then 0.8 mg/kg up to 40 mg every other week. For pediatric hidradenitis suppurativa (12 years and older): 40 mg every other week.
No specific dose adjustment recommended based on age alone; monitor for adverse effects due to potential age-related decreases in renal function.
No specific dose adjustment. Use with caution due to increased risk of infections. Monitor renal and hepatic function.
WARNING: SERIOUS INFECTIONS AND MALIGNANCY. Patients treated with TNF blockers, including Erelzi, are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue Erelzi if a patient develops a serious infection. Reported infections include: active tuberculosis (including reactivation of latent TB), invasive fungal infections (e.g., histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis), and bacterial, viral, or other opportunistic infections. Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers.
Serious infections: Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to opportunistic pathogens. Discontinue if serious infection develops. Test for latent TB prior to initiation; treat latent TB before use. Lymphoma and other malignancies: Malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers, including adalimumab. Hepatosplenic T-cell lymphoma (HSTCL) has occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers.
Serious infections: Do not start Erelzi in patients with active infections. Monitor for signs/symptoms of infection during treatment.,Malignancies: Risk of lymphoma and other malignancies; higher in children and adolescents.,Hepatitis B reactivation: Screen for HBV before starting therapy; discontinue if reactivation occurs.,Demyelinating disorders: Rare cases of CNS demyelinating disorders (e.g., multiple sclerosis, optic neuritis) reported; use caution in patients with pre-existing or recent-onset demyelinating disorders.,Congestive heart failure: Use caution in patients with heart failure; discontinue if new or worsening symptoms occur.,Hematologic events: Pancytopenia, aplastic anemia reported; advise patients to seek medical attention if signs of blood dyscrasias develop.,Hypersensitivity: Serious allergic reactions (including anaphylaxis) have been reported; discontinue if reaction occurs.,Immunizations: Avoid live vaccines during therapy.
Serious infections (including TB, invasive fungal infections, and other opportunistic infections),Malignancies (including lymphoma and HSTCL),Hepatitis B reactivation in chronic carriers,Demyelinating disease (new onset or exacerbation),Cytopenias (including pancytopenia and aplastic anemia),Congestive heart failure (worsening or new onset),Lupus-like syndrome,Serious allergic reactions (including anaphylaxis),Immunizations: Avoid live vaccines during therapy
Severe infections including sepsis,Known hypersensitivity to etanercept or any component of the product
Severe infection (e.g., sepsis, active TB),Moderate to severe heart failure (NYHA class III/IV) - relative,Known hypersensitivity to adalimumab or any component
No known food interactions. Grapefruit and other foods do not affect bimekizumab. However, maintain a balanced diet. If you have a history of liver disease, follow any dietary recommendations provided by your healthcare provider, but there are no specific restrictions.
No significant food interactions reported. Avoid alcohol if liver function is compromised.
Pregnancy Category N. No adequate animal reproduction studies. No well-controlled human studies. At therapeutic doses, immunomodulatory effects may theoretically increase risk of pregnancy loss and congenital anomalies. First trimester exposure: unknown teratogenic risk. Second and third trimester: potential for adverse fetal immune effects.
CYLTEZO (adalimumab-adaz) is a TNF-alpha inhibitor. Human data on teratogenicity are limited; however, large cohort studies do not indicate a significant increase in major birth defects. Theoretical risk of harm to the fetus due to TNF inhibition; however, placental transfer is minimal during first trimester but increases in second and third trimester. There is evidence of increased risk of infections in neonates exposed in utero during later pregnancy. Therefore, use is not recommended in the third trimester unless clearly needed.
No data on presence in breast milk. M/P ratio unknown. Maternal Ig G is known to be excreted in breast milk; as a monoclonal antibody, Erelzi may be present. Caution recommended, especially in preterm infants or those with compromised gastrointestinal barrier.
Adalimumab is excreted in human milk in low amounts; M/P ratio not established for adalimumab-adaz specifically. The molecular weight suggests it is unlikely to be absorbed by the infant in significant amounts. Expert consensus generally considers TNF-alpha inhibitors compatible with breastfeeding, but caution is advised. Monitor infant for potential adverse effects such as increased risk of infections or hypersensitivity.
No established dose adjustments for pregnancy. Pharmacokinetics of monoclonal antibodies may change due to increased plasma volume and altered metabolism. Consider therapeutic drug monitoring if available, but lack of data precludes specific dose changes.
Pharmacokinetic changes in pregnancy include increased volume of distribution and clearance, potentially requiring dose adjustments. However, there is insufficient evidence to recommend specific dose changes. Generally, continue same dose if benefit outweighs risk, but consider discontinuing in the third trimester to minimize fetal exposure, with dose adjustments as needed postpartum.
ERELZI (bimekizumab) is a humanized monoclonal Ig G1 antibody that selectively inhibits IL-17A and IL-17F. For plaque psoriasis, consider loading dose: 320 mg (two 160 mg injections) subcutaneously at weeks 0, 4, 8, then 320 mg every 8 weeks. Monitor for hypersensitivity reactions and infections. May elevate liver enzymes; check baseline and periodic LFTs. Avoid live vaccines. Can be used with caution in patients with history of inflammatory bowel disease. Injection site reactions are common; rotate sites. Not recommended in pregnancy unless benefit outweighs risk.
CYLTEZO (adalimumab-adbm) is a TNF-alpha inhibitor biosimilar to Humira. Subcutaneous injection sites should be rotated; do not inject into tender, bruised, or scarred skin. Live vaccines are contraindicated during therapy. Screen for latent TB and hepatitis B prior to initiation. Monitor for signs of infection, especially in elderly patients. Consider temporary discontinuation if serious infection occurs. May increase risk of lymphoma and other malignancies. Not recommended in patients with moderate to severe heart failure.
ERELZI is given as an injection just under the skin; you or a caregiver can be trained to inject at home.,Store in refrigerator at 36°F to 46°F (2°C to 8°C); do not freeze. Protect from light. Let it sit at room temperature for 30 minutes before injecting.,Do not use if solution is cloudy, discolored, or contains particles.,Tell your doctor if you have any signs of infection (fever, chills, cough, painful urination) or allergic reaction (rash, itching, difficulty breathing).,Avoid live vaccines during treatment.,You may need blood tests to check your liver function before and during treatment.,Seek medical attention if you develop symptoms of inflammatory bowel disease (new or worsening abdominal pain, diarrhea, blood in stool).
Cyltezo is a biosimilar of Humira and works by reducing inflammation.,Inject the medication subcutaneously as directed; rotate injection sites.,Do not receive live vaccines (e.g., MMR, chickenpox, nasal flu) while on Cyltezo.,Contact your doctor immediately if you have signs of infection (fever, cough, painful urination).,Seek medical attention for symptoms of allergic reaction (hives, difficulty breathing, swelling).,Inform your doctor if you have a history of TB, hepatitis B, heart failure, or cancer.,Store Cyltezo in the refrigerator; do not freeze. Protect from light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERELZI vs CYLTEZO, answered by our medical review team.
ERELZI is a TNF-alpha Inhibitor that works by Erelzi (etanercept-szzs) is a tumor necrosis factor (TNF) blocker. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) TNF receptor linked to the Fc portion of human Ig G1. Erelzi binds specifically to TNF-alpha and blocks its interaction with cell surface TNF receptors, thereby reducing TNF-mediated inflammatory responses.. CYLTEZO is a TNF-alpha Inhibitor that works by Adalimumab is a recombinant human monoclonal antibody that binds to tumor necrosis factor-alpha (TNFα) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecules, chemotaxis, and matrix metalloproteinases.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERELZI and CYLTEZO depend on the specific clinical indication. These are both TNF-alpha Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERELZI is: For plaque psoriasis: 100 mg subcutaneous injection once weekly, after initial loading dose of 200 mg at weeks 0, 1, 2, 3, and 4. For psoriatic arthritis: 100 mg subcutaneous injection once weekly.. The standard adult dose of CYLTEZO is: Adalimumab 40 mg subcutaneously every other week, with or without methotrexate, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. For ulcerative colitis and hidradenitis suppurativa, day 1: 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two days), day 15: 80 mg, then 40 mg every other week starting day 29. For uveitis, 40 mg every other week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERELZI and CYLTEZO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERELZI is classified as Category C. Pregnancy Category N. No adequate animal reproduction studies. No well-controlled human studies. At therapeutic doses, immunomodulatory effects may theoretically increase risk of p. CYLTEZO is classified as Category C. CYLTEZO (adalimumab-adaz) is a TNF-alpha inhibitor. Human data on teratogenicity are limited; however, large cohort studies do not indicate a significant increase in major birth de. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.